ABSTRACT
PURPOSE: To report reflux of anti-VEGF drug during intravitreal injections. METHOD: Review of electronic case notes of patients undergoing intra-vitreal anti-VEGF treatments. Prospective data collection was performed with a specific emphasis on presence or absence of reflux. RESULTS: 152 records of 102 eyes were available from an 8-month period. 119 Ranibizumab injections and 33 bevazicumab injections were considered. Reflux was noted in 48 injections (31%). For eyes with first injection of anti-VEGF agent, reflux was noted in 9/23 eyes. Eyes with at least one previous injection were observed to have reflux in 24/79 eyes. Presence of reflux was statistically tested against posterior vitreous detachment and phakic status and was found to be statistically insignificant. CONCLUSION: Intra-vitreal anti-VEGF injections with volumes of 0.05 ml appears to produce displacement of the conjunctiva with a transient fluid-filled bleb immediately after the injection in approximately 1/3 of eyes.
Subject(s)
Angiogenesis Inhibitors/administration & dosage , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vitreous Body/drug effects , Wet Macular Degeneration/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized/administration & dosage , Bevacizumab , Biological Availability , Female , Humans , Intravitreal Injections , Male , Middle Aged , Ranibizumab , Vitreous Body/metabolismABSTRACT
The authors report the case of a 68-year-old woman with secondary adenocarcinoma of the lungs from an unknown primary. Erlotinib was started which produced symptoms suggestive of uveitis. Erlotinib was stopped and restarted a month later at a lower dose, which resulted in severe bilateral anterior uveitis. The uveitis settled after stopping erlotinib and treatment with topical steroids and cycloplegics. To the best of the authors' knowledge, this is the first case of erlotinib-related anterior uveitis.
